REDWOOD CITY, Calif., Aug. 21, 2019 /PRNewswire/ -- Genomic Health today announced that, based on results from the prospective TAILORx1 and PlanB2 studies, the 16th St. Gallen International Breast ...
Genomic assays have become indispensable tools in the management of early-stage invasive breast cancer, helping oncologists move beyond traditional pathologic staging to make more ...
MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast ...
The investigators reported the results of a prospective, randomized, phase 3 trial studying the best individual therapy for women who have node-negative, estrogen-receptor‒positive (ER-positive) ...
Does agent sequencing matter across multiple lines of chemotherapy in metastatic breast cancer (MBC)?: A single institution retrospective analysis of 550 women. This is an ASCO Meeting Abstract from ...
HER2-positive early breast cancers: What proportion are receiving adjuvant trastuzumab therapy? A multicenter audit. Background: The use of traditional clinicopathologic features in decision making in ...
It was this oncologist who had a very different recommendation: Try the Oncotype DX Breast Recurrence Score® test, a ...
Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...
Please provide your email address to receive an email when new articles are posted on . Similar proportions of older women with node-negative and node-positive early breast cancer had Oncotype Dx ...
A cost-effectiveness analysis has found that Oncotype DX may not be economical to make clinical decisions on adjuvant radiation treatment in patients with DCIS. A part of precision medicine involves ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results